Cargando…

Inhibition of Colony Formation of Drug‐resistant Human Tumor Cell Lines by Combinations of Interleukin‐2‐activated Killer Cells and Antitumor Drugs

The cytotoxicity of interleukin‐2‐activated killer (LAK) cells with or without anticancer drugs against cell lines with acquired drug resistance was evaluated in vitro by colony assay. Human non‐small cell lung cancer cell lines, PC‐9 and PC‐14, human leukemia cell line, K‐562, and their sublines re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohtsu, Atsushi, Sasaki, Yasutsuna, Tamura, Tomohide, Fujiwara, Yasuhiro, Ohe, Yuichiro, Minato, Koichi, Nakagawa, Kazuhiko, Bungo, Masami, Saijo, Nagahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1989
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917724/ https://www.ncbi.nlm.nih.gov/pubmed/2498260 http://dx.doi.org/10.1111/j.1349-7006.1989.tb02303.x

Ejemplares similares

Subcutaneous Administration of Recombinant Human Granulocyte Colony‐stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer
por: Eguchi, Kenji, et al.
Publicado: (1990)

Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
por: Shinkai, Tetsu, et al.
Publicado: (1989)

Prediction from Creatinine Clearance of Thrombocytopenia and Recommended Dose in Patients Receiving (Glycolato‐O, O′)‐diammine Platinum (II) (NSC 375101D)
por: Sasaki, Yasutsuna, et al.
Publicado: (1990)

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Phase I Study of Paclitaxel by Three‐hour Infusion: Hypotension Just after Infusion Is One of the Major Dose‐limiting Toxicities
por: Tamura, Tomohide, et al.
Publicado: (1995)

A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

LEVELS OF GLUTATHIONES TRANSFERASE π mRNA IN HUMAN LUNG CANCER CELL LINES CORRELATE WITH THE RESISTANCE TO CISPLATIN AND CARBOPLATIN
por: Nakagawa, Kazuhiko, et al.
Publicado: (1988)

Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion
por: Tamura, Tomohide, et al.
Publicado: (1994)

Reversal of Cisplatin Resistance with Amphotericin B in a Non‐small Cell Lung Cancer Cell Line
por: Morikage, Toshihiko, et al.
Publicado: (1991)

Three Schedules of Recombinant Human Interleukin‐2 in the Treatment of Malignancy: Side Effects and Immunologic Effects in Relation to Serum Level
por: Sano, Tetsuro, et al.
Publicado: (1988)

A Randomized Cross‐over Study of High‐dose Metoclopramide plus Dexamethasone versus Granisetron plus Dexamethasone in Patients Receiving Chemotherapy with High‐dose Cisplatin
por: Ohmatsu, Hironobu, et al.
Publicado: (1994)

Basic Design Considerations for Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1992)

Guidelines for Analysis and Reporting of Clinical Trials in Oncology
por: Piantadosi, Steven, et al.
Publicado: (1993)

Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
por: Oshita, Fumihiro, et al.
Publicado: (1995)

The Mechanism of the Difference in Cellular Uptake of Platinum Derivatives in Non‐small Cell Lung Cancer Cell Line (PC‐14) and Its Cisplatin‐resistant Subline (PC‐14/CDDP)
por: Ohmori, Tohru, et al.
Publicado: (1993)

Pharmacokinetic Study of Mitomycin C with Emphasis on the Influence of Aging
por: Miya, Toshimichi, et al.
Publicado: (1992)

The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology
por: Saijo, Nagahiro
Publicado: (2013)

Enhancement of in vivo Antitumor Activity of a Novel Antimitotic 1‐Phenylpropenone Derivative, AM‐132, by Tumor Necrosis Factor‐cc or Interleukin‐6
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

A Limited Sampling Model for Estimating Pharmacokinetics of CPT‐11 and Its Metabolite SN‐38
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

CPT‐11 Alters the Circadian Rhythm of Dihydropyrimidine Dehydrogenase mRNA in Mouse Liver
por: Shimizu, Mikiko, et al.
Publicado: (2001)

CPT‐11: Population Pharmacokinetic Model and Estimation of Pharmacokinetics Using the Bayesian Method in Patients with Lung Cancer
por: Yamamoto, Nobuyuki, et al.
Publicado: (1994)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Alteration of Type II Regulatory Subunit of cAMP‐dependent Protein Kinase in Human Cisplatin‐resistant Cells as a Basis of Collateral Sensitivity to 8‐Chloro‐cAMP
por: Nishio, Kazuto, et al.
Publicado: (1992)

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
por: Hida, Toyoaki, et al.
Publicado: (2017)

A Novel Antitumor Antibiotic, KW‐2189 Is Activated by Carboxyl Esterase and Induces DNA Strand Breaks in Human Small Cell Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1994)

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2017)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Colonial Drugs
Publicado: (1910)

Inhibition of bone marrow colony formation by human natural killer cells and by natural killer cell-derived colony-inhibiting activity
Publicado: (1985)

Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver
por: Nakashima, Hiroyuki, et al.
Publicado: (2023)

Interferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
por: Fukumoto, Hisao, et al.
Publicado: (1997)

In vitro Enhancement of Antitumor Activity of a Water‐soluble Duocarmycin Derivative, KW‐2189, by Caffeine‐mediated DNA‐repair Inhibition in Human Lung Cancer Cells
por: Ogasawara, Hayato, et al.
Publicado: (1997)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
por: Nishio, K., et al.
Publicado: (1990)

Antitumor Responses of Invariant Natural Killer T Cells
por: Altman, Jennie B., et al.
Publicado: (2015)

The Drug Resources of the Colonies
Publicado: (1916)

CORRECTION
por: Tatsumi, Yasuaki, et al.
Publicado: (2001)

Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11
por: Sasaki, Yasutsuna, et al.
Publicado: (1995)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3tdi0sq4s6bnlopp797598hh3